Recent Advances in Breast Cancer Imaging

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Medical Imaging and Theranostics".

Deadline for manuscript submissions: 30 September 2025 | Viewed by 1549

Special Issue Editor

Special Issue Information

Dear Colleagues,

We are delighted to extend an invitation for the submission of your cutting-edge original or review research papers on breast cancer imaging. As breast cancer remains one of the most prevalent and pressing health concerns globally, the significance of advanced imaging techniques in its detection, characterization, and treatment evaluation cannot be overstated. We welcome submissions exploring a wide array of topics, including the following:

  • The development and optimization of novel imaging modalities such as magnetic resonance imaging (MRI), digital breast tomosynthesis (DBT), and contrast-enhanced mammography for early detection and risk stratification of breast lesions;
  • Advancements in quantitative imaging biomarkers and artificial intelligence algorithms to improve diagnostic accuracy, prognostication, and treatment response assessment; elucidation of the role of imaging in guiding personalized treatment strategies, including neoadjuvant chemotherapy planning, surgical margin assessment, and post-treatment surveillance;
  • Exploration of imaging-based techniques for assessing tumor heterogeneity, microenvironmental factors, and molecular subtypes to inform precision medicine approaches;
  • The integration of multimodal imaging approaches to provide comprehensive insights into the complex biology of breast cancer progression and metastasis.

We also welcome machine learning analysis of breast images. Your contributions have the potential to revolutionize breast cancer care by enhancing early detection, optimizing treatment strategies, and improving patient outcomes.

Prof. Dr. Tim Duong
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast cancer
  • neoadjuvant chemotherapy
  • axillary lymph nodes
  • molecular subtypes
  • hormonal receptor positive
  • medical oncology
  • breast surgery
  • breast cancer metastasis
  • pathological complete response
  • breast cancer recurrence

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Other

11 pages, 6381 KiB  
Article
Relationships Between Breast Edema and Axillary Lymph Node Metastasis in Breast Cancer
by Derya Deniz Altıntaş, Gul Esen Icten, Füsun Taşkın and Cihan Uras
Diagnostics 2025, 15(11), 1300; https://doi.org/10.3390/diagnostics15111300 - 22 May 2025
Viewed by 371
Abstract
Background/Objectives: To investigate the association between MRI features of primary breast cancers with axillary status, aiming to identify possible imaging biomarkers. Methods: Patients diagnosed with breast cancer between 2021 and 2023 in our clinic were retrospectively evaluated, and those that presented as mass [...] Read more.
Background/Objectives: To investigate the association between MRI features of primary breast cancers with axillary status, aiming to identify possible imaging biomarkers. Methods: Patients diagnosed with breast cancer between 2021 and 2023 in our clinic were retrospectively evaluated, and those that presented as mass lesions on preoperative MRI examinations (n: 123) were included in the study. Patients with and without metastatic axillary lymph nodes (mALN) were compared in terms of breast density, background parenchymal enhancement, tumor size, location in the breast, distance from the skin, patient age, presence of edema, multiple foci, histopathological type and molecular subtype of tumors. In multifocal/multicentric cases, the largest lesion was taken into consideration. Prepectoral and subcutaneous edema were considered diffuse edema, while perilesional edema was considered focal edema. MannWhitney U/Student-t test, Chi- square/Fischer Exact tests and logistic regression analysis were used for statistical analyses as appropriate. Results: Axilla was positive in 88 patients. There was a statistically significant difference in terms of edema, age, molecular subtype, Ki-67 index, number of lesions, tumor size, and laterality between the two groups (p < 0.05). Univariate logistic regression analysis showed that all included variables were statistically significant (p < 0.05). Multivariate logistic regression analysis revealed that presence of edema (OR: 2.46 CI; 1.11–5.48, p = 0.027) and multiple lesions (OR: 1.86 CI; 1.01–3.43, p = 0.046) were significantly associated with mALN. There was no significant difference between peritumoral edema and diffuse edema. Conclusions: Our study showed a statistically significant relationship between the axillary status and the presence of edema and multiple tumoral lesions on MRI. These findings have a potential to serve as prognostic imaging biomarkers for predicting the presence of mALN. Further studies with larger case series are needed to support our findings. Full article
(This article belongs to the Special Issue Recent Advances in Breast Cancer Imaging)
Show Figures

Figure 1

Other

Jump to: Research

15 pages, 587 KiB  
Systematic Review
Radiomics Analysis of Breast MRI to Predict Oncotype Dx Recurrence Score: Systematic Review
by Nathan Kim, Richard Adam, Takouhie Maldjian and Tim Q. Duong
Diagnostics 2025, 15(9), 1054; https://doi.org/10.3390/diagnostics15091054 - 22 Apr 2025
Viewed by 543
Abstract
Background/Objectives: The Oncotype DX recurrence score (ODXRS) has emerged as an important tool for predicting recurrence risk and guiding treatment decisions in estrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer. This review summarizes the current evidence on the clinical [...] Read more.
Background/Objectives: The Oncotype DX recurrence score (ODXRS) has emerged as an important tool for predicting recurrence risk and guiding treatment decisions in estrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer. This review summarizes the current evidence on the clinical utility of the Oncotype DX RS and explores emerging research on potential imaging-based alternatives. The 21-gene assay provides a recurrence score that stratifies patients into low, intermediate, and high-risk groups, helping to identify patients who may benefit from adjuvant chemotherapy. Multiple validation studies have demonstrated the prognostic and predictive value of the ODXRS. However, the test is costly and requires tumor tissue samples. Methods: This paper systemically reviewed the current literature on the use of radiomic analysis of breast MRI to predict Oncotype DX. The literature search was performed from 2016 to 2024 using PubMed. We compared different image types, methods of analysis, sample size, numbers of high/intermediate and low scores, MRI image types, performance indices, among others. We also discussed lessons learned and suggested future research directions. Results: Recent studies have investigated the potential of radiomics applied to breast MRI to non-invasively predict the Oncotype DX RS. Quantitative imaging features extracted from dynamic contrast-enhanced MRI, diffusion-weighted imaging, and T2-weighted sequences have shown promise for distinguishing between low and high RS groups. Multiparametric MRI-based models integrating multiple sequences have achieved the highest performance. Conclusions: While further validation is needed, MRI radiomics may offer a non-invasive, cost-effective alternative for assessing recurrence risk. Full article
(This article belongs to the Special Issue Recent Advances in Breast Cancer Imaging)
Show Figures

Figure 1

Back to TopTop